China Biologic Products Receives Forbes Honor

Oct.22.09 | About: China Biologic (CBPO)

China Biologic Products, Inc. (NASDAQ:CBPO) has been named to the 2009 list of "200 Best under a Billion" for Asia, a list put together by Forbes Magazine. China Biologic, which develops and markets plasma-based pharmaceutical products, has been growing through M&A transactions in China’s heavily regulated plasma sector.

To create its list, Forbes selects listed companies with revenues of under $1 billion, solid growth history and excellent prospects. This year’s group, which is drawn from all of Asia, includes 78 companies from China and Hong Kong.

Forbes took note that members of this year’s list had to overcome the considerable difficulties caused by the financial crisis: disrupted supply chains, frozen lines of credit, depleted consumer coffers and a shutdown in business spending. The criteria for membership wereh profitability, growth, modest indebtedness and future prospects.

Disclosure: none.